NCT06313268 - Safety of Effivia®, a Bevacizumab Biosimilar | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

April 17, 2024

Study Completion Date

September 2, 2024

Conditions

Metastatic Colorectal CancerMetastatic Cervical CancerNon Squamous Non Small Cell Lung Cancer

Interventions

DRUG

Bevacizumab Biosimilar MB02

5 mg/kg to 15 mg/kg in combination with chemotherapy.

Trial Locations (5)

Instituto Nacional de Cancerología, Tlalpan

UMAE Hospital de Especialidades No. 1, León

Hospital de Gineco-Obstetricia No. 3, Azcapotzalco

Hospital de Oncología, UMAE Centro Médico Nacional Siglo XXI, Cuauhtémoc

Hospital de Oncología IMSS Puebla, Puebla City